Kevin Rosenblatt

Dr. Rosenblatt previously served as CSO/CMO of CompanionDx Labs, a precision medicine company focused on diagnostics. With 26 years of experience as a renowned molecular pathologist and industry veteran, Dr. Rosenblatt is recognized internationally for proteomics and genomics with an emphasis on oncology, drug metabolism, and neurodegenerative diseases. He also previously served as CEO of Risk Assessment Laboratories, which focused on preterm birth biomarkers in conjunction with Perkin-Elmer.